Compare WEAV & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEAV | CMPS |
|---|---|---|
| Founded | 2011 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.1M | 598.7M |
| IPO Year | 2021 | 2020 |
| Metric | WEAV | CMPS |
|---|---|---|
| Price | $6.32 | $4.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $12.20 | ★ $16.43 |
| AVG Volume (30 Days) | 1.5M | ★ 2.2M |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $229,790,000.00 | N/A |
| Revenue This Year | $19.19 | N/A |
| Revenue Next Year | $15.09 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.34 | N/A |
| 52 Week Low | $5.64 | $2.25 |
| 52 Week High | $17.63 | $7.09 |
| Indicator | WEAV | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 48.71 | 37.83 |
| Support Level | $6.24 | $4.96 |
| Resistance Level | $6.46 | $5.57 |
| Average True Range (ATR) | 0.22 | 0.36 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 78.74 | 1.84 |
Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses, that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more, enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and revenue from subscription services.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.